These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28929751)

  • 21. Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ.
    Ozdemir ES; Jang H; Gursoy A; Keskin O; Nussinov R
    J Phys Chem B; 2018 Aug; 122(30):7503-7513. PubMed ID: 29961325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling.
    Yelland T; Garcia E; Parry C; Kowalczyk D; Wojnowska M; Gohlke A; Zalar M; Cameron K; Goodwin G; Yu Q; Zhu PC; ElMaghloob Y; Pugliese A; Archibald L; Jamieson A; Chen YX; McArthur D; Bower J; Ismail S
    J Med Chem; 2022 Feb; 65(3):1898-1914. PubMed ID: 35104933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.
    Ostrem JM; Shokat KM
    Nat Rev Drug Discov; 2016 Nov; 15(11):771-785. PubMed ID: 27469033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
    Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
    J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
    Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
    Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.
    Majrashi TA; Sabt A; Almahli H; El Hassab MA; Noamaan MA; Elkaeed EB; Hamissa MF; Maslamani AN; Shaldam MA; Eldehna WM
    PLoS One; 2024; 19(3):e0300035. PubMed ID: 38457483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction.
    Chen D; Chen Y; Lian F; Chen L; Li Y; Cao D; Wang X; Chen L; Li J; Meng T; Huang M; Geng M; Shen J; Zhang N; Xiong B
    Eur J Med Chem; 2019 Feb; 163():597-609. PubMed ID: 30562696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel PDEδ interacting proteins.
    Küchler P; Zimmermann G; Winzker M; Janning P; Waldmann H; Ziegler S
    Bioorg Med Chem; 2018 May; 26(8):1426-1434. PubMed ID: 28935183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixing a hole where the Ras gets in.
    Iwig JS; Kuriyan J
    Cell; 2013 Jun; 153(6):1191-3. PubMed ID: 23746837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
    Nishiguchi GA; Rico A; Tanner H; Aversa RJ; Taft BR; Subramanian S; Setti L; Burger MT; Wan L; Tamez V; Smith A; Lou Y; Barsanti PA; Appleton BA; Mamo M; Tandeske L; Dix I; Tellew JE; Huang S; Mathews Griner LA; Cooke VG; Van Abbema A; Merritt H; Ma S; Gampa K; Feng F; Yuan J; Wang Y; Haling JR; Vaziri S; Hekmat-Nejad M; Jansen JM; Polyakov V; Zang R; Sethuraman V; Amiri P; Singh M; Lees E; Shao W; Stuart DD; Dillon MP; Ramurthy S
    J Med Chem; 2017 Jun; 60(12):4869-4881. PubMed ID: 28557458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel KRAS‒PDE
    Chen L; Zhang J; Wang X; Li Y; Zhou L; Lu X; Dong G; Sheng C
    Acta Pharm Sin B; 2022 Jan; 12(1):274-290. PubMed ID: 35127385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substituted tetrahydroisoquinolines: synthesis, characterization, antitumor activity and other biological properties.
    Capilla AS; Soucek R; Grau L; Romero M; Rubio-Martínez J; Caignard DH; Pujol MD
    Eur J Med Chem; 2018 Feb; 145():51-63. PubMed ID: 29324343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
    Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thermodynamic, dynamic and solvational properties of PDEδ binding to farnesylated cystein: a model study for uncovering the molecular mechanism of PDEδ interaction with prenylated proteins.
    Suladze S; Ismail S; Winter R
    J Phys Chem B; 2014 Jan; 118(4):966-75. PubMed ID: 24401043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
    Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
    J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane protein transport in photoreceptors: the function of PDEδ: the Proctor lecture.
    Baehr W
    Invest Ophthalmol Vis Sci; 2014 Dec; 55(12):8653-66. PubMed ID: 25550383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells.
    Guo M; He S; Cheng J; Li Y; Dong G; Sheng C
    ACS Med Chem Lett; 2022 Feb; 13(2):298-303. PubMed ID: 35178186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
    Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
    Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors.
    Hansen R; Firdaus SJ; Li S; Janes MR; Zhang J; Liu Y; Zarrinkar PP
    Sci Rep; 2018 Sep; 8(1):14312. PubMed ID: 30254226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assay and functional properties of PrBP(PDEdelta), a prenyl-binding protein interacting with multiple partners.
    Zhang H; Hosier S; Terew JM; Zhang K; Cote RH; Baehr W
    Methods Enzymol; 2005; 403():42-56. PubMed ID: 16473576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.